Last reviewed · How we verify
AT-501 Low Dose vaccine with Adjuvant — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
AT-501 Low Dose vaccine with Adjuvant (AT-501 Low Dose vaccine with Adjuvant) — Medigen Vaccine Biologics Corp..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AT-501 Low Dose vaccine with Adjuvant TARGET | AT-501 Low Dose vaccine with Adjuvant | Medigen Vaccine Biologics Corp. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AT-501 Low Dose vaccine with Adjuvant CI watch — RSS
- AT-501 Low Dose vaccine with Adjuvant CI watch — Atom
- AT-501 Low Dose vaccine with Adjuvant CI watch — JSON
- AT-501 Low Dose vaccine with Adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). AT-501 Low Dose vaccine with Adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/at-501-low-dose-vaccine-with-adjuvant. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab